Prospective Assessment of the Deep Vein Thrombosis (DVT) in Hospitalized Obstetrics Patients

January 13, 2025 updated by: Michael A Belfort, Baylor College of Medicine
The purpose of the study is to prospectively assess the prevalence of venous thrombosis in women hospitalized for Cesarean Section, vaginal delivery or extended antepartum hospitalization by using Compression ultrasound of the entire proximal venous system of the lower limb veins.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Terminated

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

After initial admission of the patients for Cesarean Section, Vaginal Delivery or any other antepartum hospitalization, patients undergo extensive counseling regarding various aspects of the Duplex Ultrasonography procedure and the purpose of the study for screening of the venous thrombosis in asymptomatic patients. Patients electing to proceed will have written informed consent obtained and their baseline demographic and medical characteristics recorded. 48-72 hours after Cesarean Section, 24-48 hours after vaginal delivery and 48 to 72 hours after antepartum hospitalization, participants also undergo a bilateral lower extremity Venous Ultrasonographic examination which is the standard diagnostic procedure for detecting the VTE of the lower limbs. The latter group will be re-scanned 14-21 days and, when feasible, 45 days after admission.

The compression ultrasound study will be performed by post-doctoral research fellows, who will be formally trained for lower extremity ultrasound, under direct supervision. Diagnostic Criteria and Interpretation · The gray scale compression sonographic findings of acute DVT are based on direct visualization of the thrombus and lack of venous compressibility. Altered luminal echogenicity and alterations in flow characteristics are secondary signs. · Visualization of thrombus is variable, depending on the extent, age, and echogenicity (ranging from anechoic to complex) of the clot. · in case of thrombosis, Each Doppler image should demonstrate spontaneous and phasic flow. · Loss of phasic variation suggests proximal obstruction (intrinsic or extrinsic). · Prominent pulsations can be due to right sided heart failure and may be a manifestation of tricuspid valve regurgitation. Normal - Vein is totally compressible. Duplex Doppler reveals spontaneous phasic waveform Acute DVT - Vein is non compressible, but deformable and smooth. Vein is generally distended, with or without luminal echoes. The thrombus can be free floating. Spectral Doppler may be normal, continuous, or not present

If no DVT is seen on ultrasonography, then participants will be followed up clinically throughout the remainder of their hospitalization without further intervention. Participants with a DVT in the deep venous circulation will be referred to radiology for confirmation and if positive for DVT the patient will be offered treatment per current clinical guidelines for symptomatic DVT. This was the approach taken in most similar studies involving detection of DVT in asymptomatic non-pregnant women.

If a VTE is seen in the superficial veins of the lower extremity, another lower extremity venous Ultrasonographic evaluation will be scheduled 48 hours later. If a persistent superficial VTE is seen, the patient will be referred for evaluation and therapy per current clinical guidelines.

Ultrasound procedure data and all the information related to the findings of this study like the reports, ultrasound pictures or demographic informations will be stored in the subject's medical records which will be created specifically for this study.

All the imaging will be reviewed blindly by one sonographer and one radiologist for image quality. If the image is not qualified and patient is still at hospital will redo the Doppler ultrasound. if the patient is discharged will exclude that patient from the study.

We will also collect demographic data and other clinical information of the patient such as maternal age, prenatal records, ultrasounds reports at different gestational age, consultations, maternal past medical history, maternal past obstetrical history, medications receive during pregnancy, gestational age at the time of procedure, first manifestation of the DVT, treatments, process of these conditions, outcome, gestational age at birth, fetal anomalies, early neonatal outcome.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
5

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77030
        • Baylor College of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 64 years (Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All patients presenting to TCH/Women's Pavilion and Ben Taub Hospital for Cesarean Section, vaginal delivery or any antepartum hospitalization will considered for the study.

Description

Inclusion Criteria:

  • All patients hospitalized for Cesarean Section,
  • All patients hospitalized for vaginal delivery
  • any other antepartum indication of hospitalization.

Exclusion Criteria:

  • Psychiatric illness
  • social situations that could limit compliance with study activities
  • all patients who lack capacity to consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
antepartum and postpartum
This prospective, observational cohort study was designed to assess the incidence of VTE in patients hospitalized for Cesarean Section, Vaginal delivery or any antepartum indication.
Other: antepartum and postpartum
This is a prospective observational cohort study.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
incidence of Venous Thrombosis in patients hospitalized for Cesarean Section, Vaginal delivery or any antepartum indication
Time Frame: 48 hours (plus or minus 24 hours) after delivery.
48 hours (plus or minus 24 hours) after delivery.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Baylor College of Medicine

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Steven L Clark, M.D., Baylor College of Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 1, 2016

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 1, 2019

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 1, 2019

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 25, 2016

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 28, 2016

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 3, 2016

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 13, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • H-36192

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings